Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Biotts logo — Proprietary drugs in oncology, diabetology, and pain utilizi...

Biotts

Proprietary drugs in oncology, diabetology, and pain utilizing unique formulations and drug delivery technologies

Founded 2018 Poland Poland 21 employees Non Equity Assistance Total: $1.50M Biotechnology

General Information

Company Name Biotts
Founded Year 2018
Location Poland Poland
Founders / Decision Makers
Team member
Employees 21
Industries Biotechnology
Funding Stage Non Equity Assistance
Social

BounceWatch is an independent company data service, not affiliated with Biotts. To contact Biotts, visit biotts.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Biotts compare?

A PDF of Biotts and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Biotts soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Biotts

Biotts, a pioneering Polish-American biotech company, is focused on developing proprietary drugs in oncology, diabetology, and pain by leveraging unique formulations and drug delivery technologies. The company has made significant strides in the field with the breakthrough technology of its universal transdermal therapeutic system MTC-Y (Multifunctional Transdermal Carrier-Y). This carrier has demonstrated the ability to significantly enhance the bioavailability of active substances, allowing them to penetrate through the skin into soft tissues and bones. Notably, the carrier can be tailored for targeted action in pathologically changed tissues, enabling a reduction in therapeutic drug doses while maintaining efficacy and concurrently minimizing side effects. Furthermore, the system facilitates the transport of one to several active substances, providing opportunities to design multi-component drugs. Biotts, established in 2018, operates within the biotechnology sector and is headquartered in Poland. The company recently secured a Non-Equity Assistance investment on 05 October 2021, with Google for Startups participating as the investor. This strategic investment is expected to fuel the further development and advancement of Biotts' groundbreaking drug delivery technologies and proprietary drugs. With its innovative approach and strong investor support, Biotts is well-positioned to make significant contributions to the biotech industry, potentially revolutionizing the treatment landscape for oncology, diabetology, and pain management.

Business keywords: biotech company, proprietary drugs, oncology, diabetology, pain management, drug delivery technologies, transdermal drug delivery, pharmaceutical industry, bioavailability, targeted therapy, multifunctional transdermal carrier, transdermal therapeutic system, drug formulation, technical development collaborations

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Non Equity Assistance Undisclosed 1
Google for Startups
05 Oct 2021
Series A $1.50M 1
Montis Capital Group
Montis Capital Group
22 May 2020

Biotts Alternatives & Competitors

View All Alternatives
Biotts vs
Strategic Science & Technologies
Strategic Science & Technologies

Innovative technology delivering faster, effective treatments for various therapeutic areas.

Venture round
Biotechnology, Health Care
Biotts vs
Corium International
Corium International

Harnessing proprietary technologies to advance transdermal drug delivery for enhanced therapeutic ou...

Debt Financing
201-500 employees
Biotechnology, Health Care
Biotts vs
ActivX Biosciences
ActivX Biosciences United States

Was a wholly owned subsidiary of Kyorin Pharmaceutical, LTD (Tokyo, JPN: 4569.T)

15 employees
Biotechnology
Also compare with: Biotts vs Zosano Pharma Zosano Pharma View all alternatives

FAQ About Biotts

Proprietary drugs in oncology, diabetology, and pain utilizing unique formulations and drug delivery technologies
Biotts was founded in 2018.
Biotts is headquartered in Poland.
Biotts operates in Biotechnology. Its work centres on biotech company, proprietary drugs, oncology and diabetology.
Biotts has approximately 21 employees.
Biotts has completed 2 funding rounds, raising a total of $1.50M. The latest funding stage is Non Equity Assistance.
Top alternatives and competitors to Biotts include Strategic Science & Technologies, Corium International, ActivX Biosciences, Cullinan Therapeutics, AiViva Biopharma, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Biotts and Strategic Science & Technologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Biotts, https://bouncewatch.com/company/biotts, updated 1 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout